Introduction
The use of high-dose myeloablative chemo-and radiotherapy to treat cancer requires transplantation of autologous or allogeneic blood stem cells to ensure complete long-term recovery of haemopoiesis and the immune system. BM, which had to be obtained from the pelvic bone of the patient or normal donor by surgical intervention, was originally used for this purpose. 1 The use of circulating PBSC to achieve full recovery of haemopoiesis after myeloablative chemotherapy was first described in 1980. 2 As the number of haematopoietic stem cells and progenitor cells in the peripheral blood is very low under steady-state conditions, the so-called 'mobilization' methods must be used to harvest a sufficient number of cells for transplantation. In principle, this is possible by means of administration of myelotoxic chemotherapy and of haematopoietic growth factors, or a combination of these two methods.
The grounds for this method were laid by Richman, Gianni as well as Fliedner and Socinski more than 30 years ago. It was later shown that the best mobilization results were achieved with a combination of myelotoxic chemotherapy and administration of G-CSF or GM-CSF. [3] [4] [5] If an adequate number of progenitor and stem cells can be mobilized using this method and more than B2.5 million CD34 þ cells/kg body weight can be harvested by leukapheresis, recovery of haematopoiesis after transplantation of these peripheral blood stem and progenitor cells is faster than after BMT. 6, 7 For this reason, mobilization of haematopoietic progenitor cells by administration of G-CSF after myelotoxic chemotherapy is nowadays a standard method used to obtain a sufficient graft for one or more autologous blood SCTs (BSCTs).
The use of G-CSF in this context has two main objectives. On the one hand, administration of this haematopoietic growth factor shortens the duration of chemotherapy-induced neutropenia. This reduces the risk of infection-related complications that might jeopardize the harvesting of blood stem cells. 8 On the other hand, G-CSF promotes the mobilization of haematopoietic stem and progenitor cells, and thus reduces the number of apheresis procedures required. To achieve both objectives, the first dose of G-CSF must be administered within 1-6 days after completion of the chemotherapy cycle and continued daily until leukapheresis has been completed, as the half-life of non-pegylated G-CSF is only approximately 4 h. 9 A principal drawback of daily administration of G-CSF is the number of injections needed, which can have a negative impact on patient convenience and sometimes compliance, particularly if mobilization is performed under outpatient conditions.
With regard to the influence of the dose of G-CSF used for cytotoxic stem cell mobilization, the available publications provide conflicting assessments. It is agreed on that doses in the range of 5-15 mg/kg body weight produce similar results and that the dose of G-CSF administered after cytotoxic chemotherapy plays a far less important role in the extent of stem cell mobilization compared with the administration of G-CSF alone during steady state conditions. 10, 11 Other factors are more relevant to the extent of stem cell mobilization after chemotherapy, particularly the myelotoxicity of the chemotherapy, the extent of earlier chemotherapy and/or radiotherapy and the age of the patient. [11] [12] [13] As sequential high-dose therapies provide a therapeutic advantage in some disorders, such as multiple myeloma, it is of particular importance that sufficient quantities of blood stem cells are obtained during one mobilization cycle.
14 Cytotoxic blood stem cell mobilization with pegfilgrastim in patients with haematological malignancies After it had been clearly shown that a single dose of a pegylated G-CSF, after conventional chemotherapy, with prolonged half-life (pegfilgrastim) was equivalent to the daily administration of G-CSF, it seemed likely that pegfilgrastim could also be used for the mobilization of autologous haematopoietic progenitor cells. 15 The initial results obtained in limited numbers of patients with solid tumours showed that pegylated G-CSF was principally capable of mobilizing haematopoietic progenitor cells, although the results of comparative studies with conventional G-CSF were not available until recently. 16, 17 To accelerate neutrophil recovery after high-dose CY (4 g/m 2 ) and to determine the mobilization potential of pegylated G-CSF in patients with haematological malignancies, we administered 12 mg pegfilgrastim to 15 patients with multiple myeloma. 18 In this first group of patients, we decided to use a dose of pegfilgrastim that was double that usually employed after conventional chemotherapy, as very little was known at that time about the mobilization properties of the compound and the course of plasma pegfilgrastim levels after intensive myelotoxic chemotherapy. To ensure that the effects of factors, such as diagnosis and the extent of earlier chemotherapy on mobilization were reduced to a minimum, we restricted our study to patients with multiple myeloma who were treated in the context of first-line therapy. We administered a single dose of the growth factor subcutaneously on day 4 (median; range: 3-9 days) after chemotherapy. All patients received oral antibiotic and antimycotic prophylaxis during the chemotherapy-induced neutropenic phase. Patients were treated on an outpatient basis and were hospitalized only for the leukapheresis procedures or if infection-related complications arose. We started leukapheresis with a continuous flow technique as soon as the measurable concentration of CD34 þ cells in blood had increased to a value 410 ml.
In all patients, the number of PBSC harvested during the first apheresis session (median number of procedures: 1, range: 1-3) was sufficient for at least one autologous transplantation. In comparison with a similar group of patients, who were given CY and conventional G-CSF (median dose: 8.2 mg/kg body weight; range: 4.6-11.9) for mobilization, there was no significant difference with regard to the peak concentration of CD34 þ cells in peripheral blood or in the absolute number of harvested CD34 þ cells/kg body weight ( Figure 1 ). The recovery data for these two patient groups after high-dose therapy and autologous BSCT were also identical, as the peripheral blood count parameters were 100 days after the transplantation.
Interestingly, the time to neutrophil recovery after administration of CY was 2 days shorter in the pegfilgrastim group than in the group of patients who had received conventional G-CSF. This significantly faster recovery of neutrophils also meant that it was possible to perform the first leukapheresis session 2 days (median) earlier in the pegfilgrastim group. In the next phase of investigation, we halved the dose of pegfilgrastim and administered the standard dose of 6 mg pegfilgrastim in a further 15 patients with multiple myeloma after mobilization therapy with CY. 19 All aspects of the supportive therapy were identical to those for the patients in the earlier study.
We found that the time to neutrophil regeneration and to first leukapheresis after administration of 6 mg pegfilgrastim, as has been seen earlier after administration of 12 mg pegfilgrastim, was significantly shorter in comparison with the group of patients who had received conventional daily G-CSF. On the other hand, there were no significant differences to the other patient groups that had received either 12 mg pegfilgrastim or conventional G-CSF with regard to the extent of progenitor cell mobilization. In all patients, sufficient numbers of CD34 þ cells for at least one transplantation were obtained in one apheresis session (median, range: 1-3). As the determination of CD34 þ cells in the peripheral blood was initiated as soon as the WBC was higher than 1 Â 10 9 /l, a median number of two blood samples (range: 1-5) was to be analysed before the apheresis procedure in patients receiving pegfilgrastim.
Recovery data after high-dose therapy and peripheral blood parameters on day 100 after transplantation in this group were also identical to those recorded in the other two patient groups. In this study, the undesirable effects of pegfilgrastim were limited to grade 1-2 bone pain, myalgia and headache, which could easily be treated by paracetamol. Patients who received pegfilgrastim did not report any side effects that were not already known to occur with the use of conventional G-CSF.
We concluded that in patients with multiple myeloma, a single dose of 6 mg pegfilgrastim after CY is equally effective in terms of the mobilization of haematopoietic progenitor cells as daily administration of conventional G-CSF. There is no increase in this effect if the dose is doubled to 12 mg. This finding is consistent with the results of a recently published, blinded, placebo-controlled multicentre study conducted in patients with malignant lymphoma. 20 These results can be explained by the observation that a single in vivo injection of 6 mg pegfilgrastim in neutropenic patients with multiple myeloma results in plasma concentrations of B100 ng/ml, which are maintained until the time of regeneration of the neutrophilic granulocytes. 21 The levels are thus about 1-log factor higher than those achieved after administration of conventional doses of non-pegylated G-CSF, which, in turn, are 2-log factors higher than the endogenous levels of G-CSF in neutropenic patients. 22 Levels of pegfilgrastim fall only when the number of neutrophilic granulocytes and myeloid progenitor cells increases during the recovery phase after the leukocyte nadir has been passed. This fall in concentration during myeloid regeneration may be the reason why pegfilgrastim given as a single injection is not superior to conventional G-CSF with regard to the quantitative aspect of blood stem cell mobilization. For this reason, it is possible that the mobilization could be improved if the level of G-CSF was increased by means of a booster injection of either pegfilgrastim or conventional G-CSF during the early phase of haematopoietic recovery. This issue has been addressed by Tricot et al. 23 who routinely used two 6 mg doses of pegfilgrastim, on day þ 6 and on day þ 13, respectively, after DT-PACE (dexamethasone, thalidomide, cisplatin, doxorubicine, cyclophosphamide and etoposide) in 140 patients with multiple myeloma. With this dose and schedule, they found a superior mobilization of CD34 þ cells in comparison with 5 mg/kg filgrastim given twice daily from day þ 6 after DT-PACE. The median number of CD34 þ cells collected on the first apheresis day was higher (P ¼ 0.004), and a higher percentage of patients receiving pegfilgrastim collected at least 5 or 15 Â 10
þ cells in the first 3 apheresis days (89.13 vs 71.88%, Po0.0025 for 5 and 71.74 vs 17.71%, Po0.0001 for 15 Â 10 6 CD34 þ cells/kg body weight). An additional advantage compared with the use of conventional G-CSF is the faster neutrophil recovery after pegfilgrastim, which may be associated with a reduced risk of infection-related complications during neutropenia. Another benefit of cytotoxic stem cell mobilization with pegfilgrastim is the reduction of the number of injections required from 11 (median; range: 8-15) to 1 injection in our study, and from a median number of 26 to 2 injections in the study of Tricot et al., 23 which increases patient comfort and convenience. In the meantime, our results have been confirmed by other groups. [24] [25] [26] [27] Isidori et al. 24 reported on stem cell mobilization after treatment with ifosphamide (7.5 g/m ) in 25 patients with relapsed or refractory malignant lymphomas (aggressive non-Hodgkin's lymphoma: 21, Hodgkin's disease: 4). The patients were subsequently given a single dose of 6 mg pegfilgrastim 3 days after the completion of chemotherapy. All patients had been treated earlier, and 20% had received prior radiotherapy. After a median duration of grade 4 neutropenia of 1.5 days, the number of circulating CD34
þ cells peaked on day 14. It proved possible to harvest the target quantity of 2 million CD34 þ cells/kg body weight in one or more apheresis sessions in 96% of patients. The authors report that concentrations of CD34 þ cells were still elevated days after the peak had been reached. In all patients, haematopoietic recovery of leukocytes and platelets was observed between 10 and 14 days after transplantation.
Nosari et al. 25 report on 28 patients with advanced lymphomas (non-Hodgkin's lymphoma: 17, Hodgkin's disease: 11), who, after receiving a platinum-containing chemotherapy regimen, were each given 6 mg pegfilgrastim for mobilization of haematopoietic progenitor cells. The investigators also succeeded in obtaining sufficient autologous stem cells for transplantation in 27 of the 28 patients. In 25 of the patients, only a single apheresis session was required. Similar observations are reported by Kroschinsky et al. 26 in a group of 40 patients suffering from multiple myeloma or malignant lymphoma. In this patient group, additional stimulation with filgrastim during neutrophil recovery was necessary in B25% of cases, as these patients had received more intensive pre-treatment than did the other patients described in the publication (median: 2; range: 1-8 chemotherapy regimens vs median: 1; range: 1-2, Po0.001). Some of these heavily pre-treated patients had already undergone autologous BSCT or intensive radiotherapy. In 30 patients (75%), sufficient CD34 þ cells for two autologous transplantations (44 Â 10 6 /kg) were harvested. Consistent with our experience, the frequency and intensity of the undesirable effects of pegfilgrastim were low. Finally, Fruehauf et al. 27 also used a single dose of 12 mg pegfilgrastim after chemotherapy with CY, adriamycin and dexamethasone in 26 patients with multiple myeloma. During a median of two apheresis procedures (range: 1-4), 88% of patients achieved the target number of at least 7.5 million CD34 þ cells/kg body weight. When they compared the results with those of a historical control group, they found that the first apheresis could be performed significantly earlier in the group of patients who had received pegfilgrastim, which is consistent with our experience.
So far, there are no studies on the use of pegfilgrastim to mobilize haematopoietic stem cells in patients with acute leukaemia. Similarly, the use of pegylated G-CSF has not been selectively studied in the so-called 'poor mobilizers'. However, from the studies available so far, it is evident that factors that determine stem cell yield with the use of conventional G-CSF, such as age and previous therapy with stem cell toxic drugs or radiation, also apply to blood stem cell mobilization with pegfilgrastim. Therefore, pegfilgrastim alone will not completely solve the problem in 'poor mobilizers'. Strategies to combine myeloid growth factors with other cytokines, such as IL-3 or stem-cell factor have not been clinically successful in the past. 28, 29 A promising approach is to combine the CXCR-4 antagonist plerixafor with myeloid growth factors. The studies published so far show a significant increase in the mobilization of CD34 þ cells when plerixafor is added to G-CSF. 30, 31 To date, there are no published studies of plerixafor in combination with pegfilgrastim, which theoretically would be a very attractive combination.
Blood stem cell mobilization with pegfilgrastim during steady-state conditions
In addition to the mobilization of haematopoietic progenitor cells after cytotoxic chemotherapy, blood stem cells can also be mobilized into the blood by administration of a haematopoietic growth factor alone. Approximately 4 days after the daily administration of G-CSF at a dose of 8-20 mg/kg body weight, there is an increase in the number of CD34
þ cells in the blood of patients and healthy stem cell donors. With this method, the progenitor cell peak is reached between days 5 and 6. 11 The extent of mobilization is determined by the age of the patient, the diagnosis, the earlier cytotoxic therapy, the dose of G-CSF and the sequence of G-CSF administration. 32 Kroger et al., 33 for example, were able to show that mobilization was more effective if the total dose of G-CSF was divided into two equal fractions and given in the morning and in the evening rather than as a single dose once daily. In view of these results, it is possible that the continuous stimulation of haematopoiesis with pegfilgrastim during steady state could be advantageous.
In 1999, Molineux et al. 34 reported the mobilization of haematopoietic progenitor cells after the administration of pegfilgrastim in healthy volunteers for the first time. The peak concentration of CD34 þ cells in the peripheral blood was detected between days 3 and 4 depending on the dose of pegfilgrastim administered. At the highest pegfilgrastim dose of 300 mg/kg body weight, the peak was reached 1 day later than after lower doses. The side effect profile in this study was comparable to that of filgrastim.
Soon after their early experience with pegfilgrastim for cytotoxic stem cell mobilization had been gathered, Kroschinsky et al. 35 reported clinical data on the use of pegylated G-CSF in normal blood stem cell donors. Twenty-five healthy donors received a single dose of 12 mg pegfilgrastim. Additional non-pegylated G-CSF was allowed if CD34 þ cell numbers were below 5 per ml on day 3 or below 20 per ml on day 4 after pegfilgrastim administration. They observed a CD34 þ cell kinetic similar to that seen after the daily administration of conventional non-pegylated G-CSF. A peak of circulation CD34 þ cells occurred on day 5 and only one donor fulfilled the criteria to receive additional G-CSF. All donors were harvested successfully, and 20 of 25 (80%) needed just one apheresis procedure. Undesired effects were mild and included bone pain as well as headache and transient elevations of lactate dehydrogenase and alkaline phosphatase. In 2006, Hosing et al. 36 reported on 19 patients with multiple myeloma in whom blood stem cell mobilization was conducted with 12 mg pegfilgrastim without prior chemotherapy. At the time of injection of pegfilgrastim, all patients were in a phase of partial or full remission from the primary disease. Sufficient blood stem cells for two autologous transplantations were obtained from all patients. A median of two apheresis sessions (range: 1-5) was required for collection. The most common side effects of pegfilgrastim were headache and bone pain. After subsequent autologous transplantation, there was rapid recovery of haematopoiesis in all patients.
Different biological and functional properties of haematopoietic progenitor cells mobilized by pegfilgrastim in comparison with conventional G-CSF
Some of the recently published data on pegfilgrastim suggests that pegylated-G-CSF-mobilized haematopoietic progenitor cells have different biological properties when compared with CD34 þ cells mobilized by conventional G-CSF. Addressing this issue, we conducted a study on purified CD34
þ cells following cytotoxic mobilization using conventional G-CSF and pegfilgrastim, respectively. 37 Using the genome-wide array chip technique, we found higher expression levels in various genes indicative of early haematopoiesis, which translated into a different CD34 þ cell subset composition in pegfilgrastim-mobilized CD34 þ cells and altered cell cycle kinetics. On the one hand, this may be explained by a more continuous receptor stimulation mediated by pegfilgrastim in contrast with the pulsatile action of unconjugated G-CSF. On the other hand, it has been shown that the pegylation of G-CSF not only enhances serum half-life, and thus receptor occupancy, but also alters the cellular trafficking of G-CSF to enhance G-CSF receptor stimulation at a cellular level. 38 The first clinical evidence for this phenomenon has recently been presented by Tricot et al. 23 In their double transplant study on 237 myeloma patients in two consecutive protocols at the University of Arkansas, they found a significantly faster recovery of neutrophils and platelets after transplantation of pegfilgrastim-mobilized haematopoietic stem cell grafts in comparison with conventional G-CSF. The advantage of pegfilgrastim-mobilized cells disappeared during the second transplant when the number of reinfused CD34 þ cells was increased from about 4 million to more than 6 million/kg patient weight.
Distinct functional properties of G-CSF and pegfilgrastim-mobilized haematopoietic stem cell grafts have also been observed by Morris et al. 39 who showed that mobilization with pegfilgrastim results in enhanced expansion of tolerogenic APCs and augmentation of T reg activity that in turn promotes tolerance. Clearly, further studies to define the biological mechanism and possible clinical significance of these differences are needed.
Pegfilgrastim to accelerate granulocyte recovery after autologous BSCT
Recovery of leukocytes and platelets after transplantation of mobilized PBSC is faster than that after transplantation of bone marrow. 7 This translates into a reduced risk of infection-related complications, a shorter duration of hospitalization and lower costs. 40 However, even after the use of mobilized blood stem cells, there is still a phase of severe neutropenia and thrombocytopenia after high-dose chemotherapy bearing a risk of serious infections and haemorrhage. Haematopoietic growth factors, particularly G-CSF and GM-CSF, can accelerate the recovery of neutrophilic granulocytes, and thus reduce the rate of infection-related complications. 41, 42 It is for this reason that the American Society of Clinical Oncology recommends the use of G-CSF after autologous BSCT in its latest guidelines. 43 The use of pegfilgrastim to accelerate myeloid recovery after autologous BSCT seems to be particularly practical because, in contrast with conventional G-CSF, only one injection is required.
In 2003, Farese et al. 44 first reported that the administration of a single pegfilgrastim dose of 100 or 300 mg/kg body weight to accelerate haematopoietic recovery after autologous BSCT in rhesus monkeys was similarly efficacious to daily administration of filgrastim. Analysis of the plasma levels revealed that pegfilgrastim remained elevated up to the time point of neutrophilic granulocyte recovery.
We investigated the efficacy and pharmacokinetic profile of pegfilgrastim in patients with multiple myeloma who had received high-dose therapy followed by transplantation of autologous BSCT. 21 A total of 21 patients, who received 6 mg pegfilgrastim by subcutaneous injection 1 day after autologous BSCT, were enrolled in the study. We monitored plasma G-CSF levels daily from this day to the time of granulocyte recovery. In addition, we also compared clinical data from these patients with that of a group of patients who had not received a growth factor after transplantation.
The peak concentration of pegfilgrastim was reached on day 4 (median: 94 ng/ml, range: 37-205 ng/ml), and levels were maintained until day 7. With the onset of myeloid recovery and increase in neutrophilic granulocytes, the median pegfilgrastim concentration fell and reached baseline levels after complete haematopoietic recovery (Figure 2) . The level of pegfilgrastim had no effect on the duration of neutropenia. In comparison with a historical control group, leukocyte recovery occurred 5 days earlier (median: 10 days, range: 9-14 days vs median: 15 days, range: 11-29 days), and the phase of severe, grade 4 neutropenia was correspondingly shorter (Figure 3) . The required therapy for supportive care and the duration of hospitalization were also reduced in the pegfilgrastim group in comparison with the untreated patients, although the differences were not statistically significant. Notable was the fact that the elevation of neutrophils to a concentration five times the baseline level after the injection of pegfilgrastim was associated with a significant shortening of the duration of neutropenia (5 vs 7 days). A similar effect had already been observed by Straka et al. 45 after the use of filgrastim. The undesirable effects of pegfilgrastim were restricted in the vast majority of cases to headache and joint pain. One female patient suffered a rupture of the spleen after 9 days of the injection of pegfilgrastim. 46 This complication has already been reported in patients and healthy donors after the administration of conventional G-CSF, and appears to be a general risk associated with the administration of myelopoietic growth factors. 47 Similar data on pegfilgrastim serum levels and time to haematopoietic reconstitution was later reported by Piccirillo et al. ).
Review of pegfilgrastim for SC mobilization G Kobbe et al
There are currently six additional full publications dealing with the administration of pegfilgrastim after autologous BSCT and one randomized, double-blind comparison of pegfilgrastim vs filgrastim published in abstract form (Table 1) . [49] [50] [51] [52] [53] [54] Staber et al. 49 report a significantly shorter duration of neutropenia (mean: 8.3 vs 9.5 days, Po0.05) and febrile neutropenia after 30 autologous transplantations supported with pegfilgrastim treatment in comparison with an equal number of transplant procedures supported with filgrastim. In contrast, however, there were no differences in clinical parameters, especially febrile neutropenia after administration of pegfilgrastim retrospectively compared with filgrastim in a study conducted by Jagasia et al. 50 In comparison with patients who received no growth factor, the time until recovery of neutrophilic granulocytes was significantly shorter after administration of pegfilgrastim (median: 10 vs 14 days, Po0.001). In a randomized study, Martino et al. 51 observed no significant difference to filgrastim with regard to the duration of severe neutropenia when pegfilgrastim was administered at a dose of 6 mg and filgrastim at a dose of 5 mg/kg body weight. The incidence and duration of febrile neutropenia were, however, reduced in the patients receiving pegfilgrastim (61 vs 100%, and 1.5 vs 4 days). In another study, Vanstraelen et al. 52 showed that the clinical outcome after administration of pegfilgrastim was identical to that of a historical control group treated with filgrastim. Interestingly, they also report significantly higher concentrations of lymphocytes, neutrophils, reticulocytes and platelets during the first 3 months after transplantation in the patients who received pegfilgrastim. This may be consistent with our observation that pegfilgrastim, in comparison with filgrastim, leads to the stimulation of less mature haematopoietic progenitor ). Difference not significant.
Review of pegfilgrastim for SC mobilization G Kobbe et al cells. 37 Finally, in a randomized, double-blind, placebocontrolled comparative trial of pegfilgrastim vs conventional G-CSF reported in the annual meeting of the American Society for Hematology in 2007, Gerds et al. 54 did not find significant clinical differences in the outcome of either patient group. However, patients who had received pegfilgrastim were less likely to experience an early overshoot of granulocytes (410.000 per ml) during haematopoietic recovery. In all investigations, significantly fewer injections were needed in patients receiving pegfilgrastim.
Cost-effectiveness of pegfilgrastim
To date, only a limited number of economic analyses are available on the use of pegfilgrastim during haematopoietic progenitor cell mobilization or transplantation. 53, 54 Obviously, pegfilgrastim is much more expensive than unconjugated G-CSF, but a reduced number of injections and apheresis procedures as well as a lower incidence of febrile neutropenia in addition to a possibly greater efficacy in terms of stem cell quality may offset the increased price of the drug. Several economic studies on growth factor therapy, including pegfilgrastim, that have been conducted in cancer patients receiving chemotherapy suggest that pegfilgrastim is cost-effective. [55] [56] [57] [58] However, in general, these studies cannot be extrapolated to the use of pegfilgrastim in the context of SCT. Appropriate studies are needed to address this issue.
Conclusion
The cumulative body of evidence indicates that the mobilization of haematopoietic stem and progenitor cells using a single injection of pegfilgrastim is safe and efficient, both after cytotoxic chemotherapy and after administration of the growth factor on its own. A dose of 6 mg pegfilgrastim is sufficient for cytotoxic mobilization, and dose escalation does not improve mobilization. The only dose that has been successfully used so far for steady-state mobilization is 12 mg. Data published to date indicate that pegfilgrastim is at least equal to conventional G-CSF with regard to the extent of stem cell mobilization, and further reduces the duration of neutropenia after chemotherapy. However, as growth factor-induced mobilization of haematopoietic progenitor cells is subject to considerable interindividual variation and most studies published so far were rather small, larger randomized studies will be necessary to directly compare the effectiveness of pegfilgrastim and conventional G-CSF. In addition, studies on the biology of pegfilgrastim-mobilized CD34 þ cells are needed, as recently published data suggest biological and functional differences between haematopoietic stem cells mobilized by conventional or pegylated G-CSF.
After high-dose therapy and autologous BSCT, the administration of a single dose of 6 mg pegfilgrastim results in a comparable time needed for the recovery of neutrophil granulocytes as daily administration of filgrastim or lenograstim. Owing to its pharmacokinetic properties, pegfilgrastim induces high plasma concentrations of G-CSF after a single injection, and these fall back to normal levels only after the onset of neutrophil recovery. Some of the available data indicate that the incidence and duration of febrile neutropenia may be favourably influenced by the use of pegfilgrastim.
